论文部分内容阅读
目的测定颅内支架术治疗前后患者C-反应蛋白(CRP)的水平,探讨阿托伐他汀对预防患者颅内支架再狭窄的可能性。方法将42例颅内支架患者随机分为对照组和治疗组(n=21)。对照组口服玻立维75mg+拜阿司匹林100mg,1次/d;治疗组口服阿托伐他汀40mg(术前7d开始)+玻立维75mg+拜阿司匹林100mg,1次/d。术前7d及1d,术后7d、3个月、6个月采用免疫透射比浊法分别测血清CRP水平。结果与对照组术前1d(7.44±0.73)mg/L、术后7d(27.61±1.81)mg/L、术后3个月(36.46±1.67)mg/L、术后6个月(26.84±0.76)mg/L比较,治疗组同期的CRP明显下降(P<0.05);与术后7d(12.05±0.55mg/L)比较,治疗组术前1d(6.22±0.57)mg/L、术后3个月(6.03±0.46)mg/L、6个月(6.12±0.77)mg/L下降明显(P<0.01);术前1d、术后3个月、6个月之间差异无统计学意义(P>0.05)。结论阿托伐他汀可有效抑制炎症因子,是预防支架内再狭窄的有效治疗方法之一。
Objective To determine the level of C-reactive protein (CRP) in patients with intracranial stenting before and after treatment and to explore the possibility of atorvastatin in preventing the restenosis of intracranial stents. Methods Forty-two patients with intracranial stents were randomly divided into control group and treatment group (n = 21). The patients in the control group were orally given 75mg of vitreous and 100mg of aspirin once a day. The treatment group was treated with atorvastatin 40mg (preoperatively 7d) + 75mg vitiligo + aspirin 100mg once daily. Preoperative 7d and 1d, postoperative 7d, 3 months, 6 months using immunoturbidimetry were measured serum CRP levels. Results Compared with the control group, the levels of IL-6 and IL-6 in the control group were significantly higher than those in the control group (7.44 ± 0.73 mg / L before operation, 27.61 ± 1.81 mg / L after operation, 36.46 ± 1.67 mg / L at 3 months and 26.84 ± (P <0.05). Compared with the control group (P <0.05), the CRP of the treatment group was significantly lower than that of the control group (0.76 mg / L) (6.03 ± 0.46) mg / L for 3 months and 6.12 ± 0.77 mg / L for 6 months (P <0.01). There was no significant difference between the first 3 days and the 3rd postoperative 6 months Significance (P> 0.05). Conclusions Atorvastatin can effectively inhibit inflammatory cytokines and is one of the effective treatments to prevent in-stent restenosis.